Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a common and potentially serious chronic inflammatory respiratory disease. It has an estimated prevalence of 12% in Europe, making it a major public health issue. It is currently the third leading cause of death worldwide and affects a higher proportion of men (sex ratio 1.5:1.9). The main risk factor is cigarette smoke exposure (whether active or passive), responsible for 80% of cases. Exposure to other agents such as fine particles and fuel smoke can also lead to the development of the disease. Finally, a favourable genetic background is now commonly accepted as a risk factor.

COPD diagnosis is based on lung function measurement : non-reversible obstructive respiratory syndrome, i.e. a Tiffeneau coefficient (FEV1/FVC) < 70% after inhalation of a bronchodilator agent. At the pulmonary level, it is characterized by bronchial remodeling associated with parenchymal destruction, resulting on the one hand in peribronchial fibrosis, and on the other hand in emphysema bullae related to the rupture of the alveolar walls.

Its management is global and combines a series of medicinal and non-medicinal measures: use of bronchodilators and inhaled corticosteroids, smoking cessation (if applicable), prevention strategies including vaccination, physical management such as respiratory rehabilitation and management of comorbidities.

Indeed, COPD is currently considered a systemic disease with predominantly respiratory involvement associated with numerous comorbidities. These include cardiovascular disease, osteoporosis, depression, bronchopulmonary cancer and muscle dysfunction. The latter is characterized by a decrease in muscle strength and volume and is also called sarcopenia. Sarcopenia is present in 4 to 66% of patients and is associated with a particularly severe patient profile, since patients with low muscle mass have a mortality 13 times higher than patients with normal muscle mass (after adjustment for respiratory function).

Sarcopenia is defined by the loss of both muscle mass and strength, and extensive work has been done in the geriatric population, leading to the drafting of European recommendations which are considered applicable in the COPD population. Thus, sarcopenia can be defined by a decrease in the appendicular muscle mass index (ASM or Appendicular Skeletal Muscle Mass divided by height) measured by dexametry (or biphotonic X-ray absorptiometry), of less than 7.0 kg/m2 in men and 5.5 kg/m2 in women. However, although the measurement of lean body mass is recommended by both the HAS (COPD care pathway guide) and the latest recommendations of the Société de Pneumologie de Langue Française (French language lung society), this condition is currently largely under-diagnosed in COPD patients. Moreover, there is no specific treatment for sarcopenia: the only intervention that has been shown to be effective is exercise training as part of respiratory rehabilitation.

Numerous studies have described the histological changes characterizing muscle damage in COPD patients, particularly in the quadriceps. These include a decrease in the diameter and vascularization of muscle fibers, associated with a change in fiber metabolism: disappearance of type I fibers (predominantly oxidative metabolism) in favor of type II fibers (glycolytic metabolism). Local inflammation is also observed, sometimes associated with necrosis and an increase in the percentage of regenerating fibers. However, the originating mechanisms are still largely unknown.

Fibrocytes are cells derived from blood monocytes and able to migrate from the blood flow to different organs. They can exert pro-fibrotic functions by secreting collagen themselves or activating collagen secretion by fibroblasts. This is notably the case in the lung of COPD patients, where they play a key role in bronchial obstructive disease: they are recruited in the blood during an acute exacerbation of COPD, and their density is increased at the peribronchial level and negatively correlated with the parameters of lung function.

However, they may also play a pro-inflammatory role and influence the metabolism of resident cells. It has recently been shown that their differentiation is accompanied by a metabolic reprogramming that promotes oxidative phosphorylation. Moreover, recent data obtained in a mouse model show their involvement in tissue repair after muscle injury.

Because of their capacity to secrete pro-inflammatory factors and their possible influence on the metabolism of myofibers, studying their role in the development of sarcopenia in COPD patients could therefore be a promising avenue. Moreover, due to their preferential recruitment via a CXCL12/CXCR4 chemotactic axis, the migration of these cells towards damaged tissues (lung, muscle) of COPD patients would potentially respond to a therapeutic strategy by CXCR4 modulation.

Inclusion criteria

• Men or women 40 years of age or older;
• Diagnosed with COPD according to the 2018 Global Initiative for Lung Disease (GOLD) criteria:

• Smoking intoxication greater than or equal to 10 pack-years
• Bronchial obstruction on spirometry with a FEV1 to FVC ratio post-bronchodilator < 70%.
• Available measurement of lean body mass by bioelectrical impedancemetry performed as part of routine care;
• Insured under the French social security system;
• Informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

The patients included will be sarcopenic and non-sarcopenic (equal numbers in each group, patients categorized according to the result of dexametry), and will be matched on sex and age (± 5 years).

Exclusion criteria

• Other concomitant respiratory pathology (e.g., asthma);
• Acute exacerbation of COPD or acute intercurrent condition (e.g. infection) ongoing or resolved within the last 48 hours
• Current systemic corticosteroid therapy;
• Contraindication to muscle biopsy: acquired or innate hemostasis disorders, anticoagulant therapy or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias;
• Presence of a concomitant muscular pathology, innate (e.g. genetic myopathy) or acquired (e.g. myositis);
• Progressive bronchopulmonary cancer;
• Pregnant or breast-feeding woman;
• Patient undergoing respiratory rehabilitation;
• Refusal to participate in the study.

Exclusion criteria

between V1 and V2:

• Disorders of hemostasis detected on the blood sample;
• Pregnancy in progress.